文献速递心脑血管急症重症综合管理与镇静镇痛

COVID-19 心血管疾病负担:系统评价与荟萃分析

Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis.
PubMed 文献 · Am J Emerg Med · 2020-10-16
一句话结论COVID-19 患者中急性心肌损伤、心律失常、心衰、冠心病、高血压均与死亡和 ICU 入住显著相关,应加强监测与处理。

结果显示急性心肌损伤、高血压、心衰、心律失常、冠心病及心血管疾病与死亡显著相关;心律失常、急性心肌损伤、冠心病、心血管疾病及高血压与 ICU 入住显著相关。结论推荐对 COVID-19 合并心血管疾病患者进行规范管理,并对 COVID-19 患者监测急性心脏情况以预防死亡和危重症。

要点

  • 急性心肌损伤与 COVID-19 患者死亡显著相关(OR 13.29,95%CI 7.35-24.03),与 ICU 入住也显著相关(OR 15.58,95%CI 5.15-47.12)。
  • 心律失常与死亡(OR 2.75,95%CI 1.43-5.25)及 ICU 入住(OR 7.03,95%CI 2.79-17.69)均显著相关。
  • 心衰与死亡显著相关(OR 6.72,95%CI 3.34-13.52),冠心病与死亡(OR 3.78,95%CI 2.42-5.90)及 ICU 入住(OR 2.61,95%CI 1.09-6.26)显著相关。
  • 高血压与死亡(OR 2.60,95%CI 2.11-3.19)及 ICU 入住(OR 1.95,95%CI 1.41-2.68)显著相关,心血管疾病整体亦与死亡(OR 2.61,95%CI 1.89-3.62)和 ICU 入住(OR 3.11,95%CI 1.59-6.09)相关。
  • 建议对 COVID-19 合并心血管疾病患者进行适当管理,并对 COVID-19 患者监测急性心脏情况以预防死亡和危重症。

适用人群与场景

  • COVID-19 患者,包括合并心血管疾病(高血压、冠心病、心衰、心律失常等)者;研究覆盖住院及 ICU 场景,具体纳入/排除标准原文未提及。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文推荐对 COVID-19 合并心血管疾病患者进行适当管理,并对 COVID-19 患者监测急性心脏情况以预防死亡和危重症;具体药物、剂量、监测方案原文未提及。

红旗征与不能漏的情况

  • 急性心肌损伤、心律失常、心衰、冠心病、高血压等心血管疾病与 COVID-19 患者死亡和 ICU 入住显著相关,需警惕并处理;具体处理措施原文未提及。

研究设计与关键结果

  • 死亡结局:急性心肌损伤 OR 13.29(95%CI 7.35-24.03),高血压 OR 2.60(95%CI 2.11-3.19),心衰 OR 6.72(95%CI 3.34-13.52),心律失常 OR 2.75(95%CI 1.43-5.25),冠心病 OR 3.78(95%CI 2.42-5.90),心血管疾病 OR 2.61(95%CI 1.89-3.62)。
  • ICU 入住结局:心律失常 OR 7.03(95%CI 2.79-17.69),急性心肌损伤 OR 15.58(95%CI 5.15-47.12),冠心病 OR 2.61(95%CI 1.09-6.26),心血管疾病 OR 3.11(95%CI 1.59-6.09),高血压 OR 1.95(95%CI 1.41-2.68)。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析;证据等级或推荐强度原文未提及;局限:原文未明确提及,但纳入研究多为观察性设计,异质性可能影响合并估计。

对床旁实践的改变

  • 对 COVID-19 患者应监测急性心脏情况(如急性心肌损伤、心律失常、心衰),尤其合并心血管疾病者,以预防死亡和 ICU 入住;具体监测手段和处理流程原文未提及。

指南或共识出处

  • 原文未提及指南或共识名称;本文为系统评价与荟萃分析,发表于 Am J Emerg Med。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: High rate of cardiovascular disease (CVD) have been reported among patients with novel coronavirus disease (COVID-19). Meanwhile there were controversies among different studies about CVD burden in COVID-19 patients. Hence, we aimed to study CVD burden among COVID-19 patients, using a systematic review and meta-analysis.

METHODS: We have systematically searched databases including PubMed, Embase, Cochrane Library, Scopus, Web of Science as well as medRxiv pre-print database. Hand searched was also conducted in journal websites and Google Scholar. Meta-analyses were carried out for Odds Ratio (OR) of mortality and Intensive Care Unit (ICU) admission for different CVDs. We have also performed a descriptive meta-analysis on different CVDs.

RESULTS: Fifty-six studies entered into meta-analysis for ICU admission and mortality outcome and 198 papers for descriptive outcomes, including 159,698 COVID-19 patients. Results of meta-analysis indicated that acute cardiac injury, (OR: 13.29, 95% CI 7.35-24.03), hypertension (OR: 2.60, 95% CI 2.11-3.19), heart Failure (OR: 6.72, 95% CI 3.34-13.52), arrhythmia (OR: 2.75, 95% CI 1.43-5.25), coronary artery disease (OR: 3.78, 95% CI 2.42-5.90), and cardiovascular disease (OR: 2.61, 95% CI 1.89-3.62) were significantly associated with mortality. Arrhythmia (OR: 7.03, 95% CI 2.79-17.69), acute cardiac injury (OR: 15.58, 95% CI 5.15-47.12), coronary heart disease (OR: 2.61, 95% CI 1.09-6.26), cardiovascular disease (OR: 3.11, 95% CI 1.59-6.09), and hypertension (OR: 1.95, 95% CI 1.41-2.68) were also significantly associated with ICU admission in COVID-19 patients.

CONCLUSION: Findings of this study revealed a high burden of CVDs among COVID-19 patients, which was significantly associated with mortality and ICU admission. Proper management of CVD patients with COVID-19 and monitoring COVID-19 patients for acute cardiac conditions is highly recommended to prevent mortality and critical situations.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Hessami A, Shamshirian A, Heydari K, et al. Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis. Am J Emerg Med. 2020. PMID: 33268238. doi:10.1016/j.ajem.2020.10.022

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。